| Date Filed | Type | Description |
| 07/03/2023 |
4
| Sigal Charles Elliott (Director) has filed a Form 4 on Adaptimmune Therapeutics PLC|
Txns:
| Granted 933,317 options to buy
@ $0 |
|
| 05/24/2023 |
4
| Sigal Charles Elliott (Director) has filed a Form 4 on Vir Biotechnology, Inc.|
Txns:
| Granted 6,027 shares
@ $0
Granted 12,054 options to buy
@ $25.74, valued at
$310.3k
|
|
| 05/19/2023 |
4
| Sigal Charles Elliott (Director) has filed a Form 4 on ALNYLAM PHARMACEUTICALS, INC.|
Txns:
| Granted 3,454 options to buy
@ $189.87, valued at
$655.8k
|
|
| 03/02/2023 |
4
| Sigal Charles Elliott (Director) has filed a Form 4 on Vir Biotechnology, Inc.|
Txns:
| Bought 2,500 shares
@ $22.7262, valued at
$56.8k
|
|
| 01/09/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 01/05/2023 |
4
| Sigal Charles Elliott (Director) has filed a Form 4 on Vir Biotechnology, Inc.|
Txns:
| Bought 2,500 shares
@ $25.597, valued at
$64k
Bought 2,500 shares
@ $25.2545, valued at
$63.1k
|
|
| 08/24/2022 |
4
| Sigal Charles Elliott (Director) has filed a Form 4 on ALNYLAM PHARMACEUTICALS, INC.|
Txns:
| Granted 4,456 options to buy
@ $217.91, valued at
$971k
|
|
| 08/24/2022 |
3
| Sigal Charles Elliott (Director) has filed a Form 3 on ALNYLAM PHARMACEUTICALS, INC. |
| 07/01/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 06/10/2022 |
4
| Sigal Charles Elliott (Director) has filed a Form 4 on Surface Oncology, Inc.|
Txns:
| Granted 24,000 options to buy
@ $2.01, valued at
$48.2k
|
|
| 05/25/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 07/02/2021 |
4
| Sigal Charles Elliott (Director) has filed a Form 4 on Adaptimmune Therapeutics PLC|
Txns:
| Granted 474,385 options to buy
@ $0 |
|
| 06/10/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 05/25/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 10/13/2020 |
4/A
| Form 4/A - Statement of changes in beneficial ownership of securities: [Amend] |
| 07/14/2020 |
4
| Sigal Charles Elliott (Director) has filed a Form 4 on Vir Biotechnology, Inc.|
Txns:
| Granted 57,777 options to buy
@ $48.71, valued at
$2.8M
|
|
| 07/14/2020 |
3
| Sigal Charles Elliott (Director) has filed a Form 3 on Vir Biotechnology, Inc. |
| 07/01/2020 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 06/12/2020 |
4
| Sigal Charles Elliott (Director) has filed a Form 4 on Surface Oncology, Inc.|
Txns:
| Granted 12,000 options to buy
@ $4.35, valued at
$52.2k
|
|
| 10/03/2019 |
4
| Sigal Charles Elliott (Director) has filed a Form 4 on Surface Oncology, Inc.|
Txns:
| Granted 13,572 options to buy
@ $1.17, valued at
$15.9k
|
|
| 07/03/2019 |
4
| Sigal Charles Elliott (Director) has filed a Form 4 on Adaptimmune Therapeutics PLC|
Txns:
| Granted 234,407 options to buy
@ $0 |
|
| 06/06/2019 |
4
| Sigal Charles Elliott (Director) has filed a Form 4 on Surface Oncology, Inc.|
Txns:
| Granted 12,100 options to buy
@ $3.69, valued at
$44.6k
|
|
| 07/05/2018 |
4
| Sigal Charles Elliott (Director) has filed a Form 4 on Surface Oncology, Inc.|
Txns:
| Granted 8,882 options to buy
@ $16.83, valued at
$149.5k
|
|
| 06/26/2018 |
4
| Sigal Charles Elliott (Director) has filed a Form 4 on Adaptimmune Therapeutics PLC|
Txns:
| Granted 154,809 options to buy
@ $0 |
|
| 04/23/2018 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 04/18/2018 |
3
| Sigal Charles Elliott (Director) has filed a Form 3 on Surface Oncology, Inc. |
| 07/03/2017 |
4
| Form 4 - Statement of changes in beneficial ownership of securities |
| 05/19/2016 |
4
| Sigal Charles Elliott (Director) has filed a Form 4 on Adaptimmune Therapeutics PLC|
Txns:
| Bought 15,000 shares
@ $1.56, valued at
$23.4k
|
|
| 05/18/2016 |
4
| Sigal Charles Elliott (Director) has filed a Form 4 on Adaptimmune Therapeutics PLC|
Txns:
| Bought 15,000 shares
@ $1.5, valued at
$22.5k
Bought 15,000 shares
@ $1.53, valued at
$23k
Bought 15,000 shares
@ $1.55, valued at
$23.3k
|
|